Anesiva's media center is designed to provide reporters with easy access to news about the company and its products for stories in development. If you don't find what you are looking for or need more information, please contact us.
All Releases |
|
Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
Oct 16, 2007
|
12.9 KB
|
|
SOUTH SAN FRANCISCO, Calif., Oct 16, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced positive top-line results from its pivotal Phase 3 trial. The multi-center, randomized, double-blind study with 699 adult patients met its primary endpoint, demonstrating less venous procedural pain in those treat...
|
|
|
Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
Oct 12, 2007
|
17.3 KB
|
|
SOUTH SAN FRANCISCO, Calif., Oct 12, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced key elements of the company's commercialization and launch plans for Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, to reduce pain associated with peripheral venous access pro...
|
|
|
Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
Oct 11, 2007
|
14.3 KB
|
|
SOUTH SAN FRANCISCO, Calif. and SCHAUMBURG, Ill., Oct 11, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) and Sagent Pharmaceuticals, Inc., today announced an agreement in which Sagent will co-promote for three years Anesiva's Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection product an...
|
|
|
Anesiva Defines Regulatory Pathway for Adlea with FDA
Oct 10, 2007
|
13.0 KB
|
|
SOUTH SAN FRANCISCO, Calif., Oct 10, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that it will conduct two Phase 3 clinical trials for the approval of Adlea(TM) -- one of which has already been planned in total knee replacement surgeries -- and the second trial in bunionectomy surgeries -- for ...
|
|
|
Anesiva to Present at BIO InvestorForum on October 11, 2007
Oct 5, 2007
|
8.5 KB
|
|
SOUTH SAN FRANCISCO, Calif., Oct 05, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that John P. McLaughlin, the company's chief executive officer, will present at the Biotechnology Industry Organization's "BIO InvestorForum 2007" on Thursday, October 11, 2007 at 9:30 am PDT in San Francisco.
...
|
|
|